CY1801A - 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives - Google Patents

1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives

Info

Publication number
CY1801A
CY1801A CY180195A CY180195A CY1801A CY 1801 A CY1801 A CY 1801A CY 180195 A CY180195 A CY 180195A CY 180195 A CY180195 A CY 180195A CY 1801 A CY1801 A CY 1801A
Authority
CY
Cyprus
Prior art keywords
benzisothiazol
benzisoxazol
derivatives
Prior art date
Application number
CY180195A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26664247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1801A publication Critical patent/CY1801A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
CY180195A 1985-03-27 1995-02-17 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives CY1801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71706785A 1985-03-27 1985-03-27
SG119294A SG119294G (en) 1985-03-27 1994-08-20 1,2-benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives

Publications (1)

Publication Number Publication Date
CY1801A true CY1801A (en) 1995-02-17

Family

ID=26664247

Family Applications (1)

Application Number Title Priority Date Filing Date
CY180195A CY1801A (en) 1985-03-27 1995-02-17 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives

Country Status (15)

Country Link
US (1) US4804663A (fr)
EP (1) EP0196132B1 (fr)
JP (1) JPH0613511B2 (fr)
CN (1) CN1022566C (fr)
AU (1) AU579232B2 (fr)
BG (1) BG60432B2 (fr)
CA (1) CA1256867A (fr)
CY (1) CY1801A (fr)
DK (1) DK168537B1 (fr)
HK (1) HK108794A (fr)
IE (1) IE58388B1 (fr)
LU (1) LU88576I2 (fr)
NL (1) NL940006I2 (fr)
SG (1) SG119294G (fr)
SU (1) SU1468419A3 (fr)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335289C (fr) * 1987-10-26 1995-04-18 Fujio Antoku Derives piperidinylbenzisoxazole, leur production et leur utilisation pharmaceutique
US5116970A (en) * 1988-02-18 1992-05-26 New James S Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
US5001130A (en) * 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
GR1000667B (el) * 1988-03-21 1992-09-25 Janssen Pharmaceutica Nv Μεθοδος παρασκευης 3-πιπεριδινυλο-1,2-βενζισοξαζολων.
US4957916A (en) * 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US5015740A (en) * 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
NZ230045A (en) 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
IL90879A0 (en) * 1988-09-02 1990-02-09 Janssen Pharmaceutica Nv 3-piperidinyl-indazole derivatives,their preparation and antihypertensive compositions containing them
US5196425A (en) * 1988-09-02 1993-03-23 Janssen Pharmaceutica N.V. Antihypertensive 3-piperidinyl-indazole derivatives
US5321028A (en) * 1988-09-02 1994-06-14 Janssen Pharmaceutica N.V. Antihypertensive 3-piperidinyl-indazole derivatives
CA2000786C (fr) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5153206A (en) * 1988-12-02 1992-10-06 Pfizer Inc. Arylpiperidine derivatives
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
US5256659A (en) * 1989-01-09 1993-10-26 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
GB8900382D0 (en) * 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2671350A1 (fr) * 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
US5075315A (en) * 1990-05-17 1991-12-24 Mcneilab, Inc. Antipsychotic hexahydro-2H-indeno[1,2-c]pyridine derivatives
DE69105501T2 (de) * 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US5147881A (en) * 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
CA2116117A1 (fr) * 1991-08-22 1993-03-04 Hiroyuki Sueoka Compose de type benzisoxazole et son utilisation
ATE146178T1 (de) * 1991-09-25 1996-12-15 Pfizer Neuroleptisch 2-substituierte perhydro-1h- pyrido(1,2-a>pyrazine
US5532243A (en) * 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
DE4243287A1 (de) * 1992-06-19 1993-12-23 Basf Ag N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
JPH07508741A (ja) * 1992-07-13 1995-09-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新規４−（３−ベンゾフラニル）ピペリジニル及び４−（３−ベンゾチエニル）ピペリジニル誘導体，ならびにそれらを含む製薬学的組成物
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
AU687940B2 (en) * 1993-11-23 1998-03-05 Janssen Pharmaceutica N.V. Novel 9-hydroxy-pyrido(1,2-a)pyrimidin-4-one ether derivatives
ES2074966B1 (es) * 1994-02-11 1996-06-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il)piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a)pirimidin-4-ona.
ES2085234B1 (es) * 1994-02-24 1997-01-16 Vita Invest Sa Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
CA2144669A1 (fr) 1994-03-29 1995-09-30 Kozo Akasaka Derives du biphenyle
EP0794185A4 (fr) * 1994-11-25 1998-03-25 Meiji Seika Co Compose thiazole bicyclique
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
ES2253748T3 (es) 1995-02-28 2006-06-01 H. Lundbeck A/S Compuestos 4-aminotetrahidro bencisoxazol o isotiazol.
TW592729B (en) * 1995-04-06 2004-06-21 Janssen Pharmaceutica Nv Rate-controlled transdermal administration of risperidone
KR960042947A (ko) * 1995-05-09 1996-12-21 김주용 고집적 반도체 소자 및 그 국부 연결 방법
ES2097093B1 (es) * 1995-05-26 1998-01-16 Ferrer Int Nuevos compuestos derivados de 5h-tiazolo (3,2-a) pirimidin-5-ona.
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
WO2001085731A1 (fr) * 2000-05-05 2001-11-15 Rpg Life Sciences Limited Procede de preparation de 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2,-a]pyrimidin-4-one antipsychotique
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2001284763A1 (en) * 2000-08-08 2002-02-18 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
EP1783118B1 (fr) * 2000-08-14 2008-07-16 Teva Pharmaceutical Industries Ltd. Préparation de rispéridone
HUP0302874A2 (hu) * 2000-08-14 2003-12-29 Teva Pharmaceutical Industries Ltd. Eljárás risperidon előállítására
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US6730772B2 (en) 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
ES2398434T3 (es) * 2001-08-31 2013-03-19 Novartis Ag Isómeros ópticos de un metabolito de iloperidona
HU227118B1 (en) * 2001-11-13 2010-07-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
SI1458888T1 (sl) * 2001-12-10 2011-07-29 Novartis Ag Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntf
ES2197801B1 (es) 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
WO2004009591A1 (fr) * 2002-07-22 2004-01-29 Aurobindo Pharma Ltd. Procede de preparation de risperidone antipsychotique
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1534288A1 (fr) * 2002-08-23 2005-06-01 Ranbaxy Laboratories, Ltd. Solutions aqueuses stables de risperidone et leurs methodes de preparation
WO2004020439A2 (fr) * 2002-08-30 2004-03-11 Sunil Sadanand Nadkarni Procede de preparation de risperidone ameliore
KR20040025224A (ko) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
EP1560814A1 (fr) 2002-11-13 2005-08-10 Synthon B.V. Procede de fabrication de la risperidone et des intermediaires associes
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
WO2004064752A2 (fr) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Procede de preparation de microparticules a liberation prolongee
WO2004094415A1 (fr) * 2003-04-22 2004-11-04 Synthon B.V. Monochlorhydrates de risperidone
MXPA05012317A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
WO2005030772A1 (fr) * 2003-09-26 2005-04-07 Jubilant Organosys Ltd. Procede de preparation de risperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
CN1870980B (zh) * 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005051919A1 (fr) * 2003-11-26 2005-06-09 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
EP1737473A4 (fr) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Combinaisons de lithium et utilisations associees
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
US20060004199A1 (en) * 2004-07-01 2006-01-05 Dr. Reddy's Laboratories Limited Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
JP4912312B2 (ja) * 2004-08-24 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体
ATE413166T1 (de) * 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
EP1863485A2 (fr) * 2005-03-18 2007-12-12 Abbott Laboratories Ligand du recepteur nicotinique neuronal alpha7 et compositions antipsychotiques
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
WO2006129160A2 (fr) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Solutions aqueuses stables d'un agent antipsychotique
EP1933814A2 (fr) * 2005-09-15 2008-06-25 Elan Pharma International Limited Formulations aripiprazoliques nanoparticulaires
US20070134310A1 (en) * 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
JP4922657B2 (ja) * 2006-05-09 2012-04-25 高田製薬株式会社 リスペリドン経口用液剤
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
KR20090029200A (ko) * 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
EP2041304B1 (fr) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Génotypes rgs2 associés aux symptômes extrapyramidaux induits par un médicament antipsychotique
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
WO2008021345A2 (fr) 2006-08-14 2008-02-21 Teva Pharmaceutical Industries Ltd. Procédé de synthèse de la 9-hydroxy-rispéridone (palipéridone)
WO2008047340A1 (fr) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Thérapies combinées d'antipsychotiques et de tétracyclines dans le traitement de troubles psychiatriques
PT2083811T (pt) 2006-11-22 2017-01-23 Clinical Res Ass Llc Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
WO2008087557A2 (fr) * 2007-01-08 2008-07-24 Actavis Group Ptc Ehf Procédé amélioré de préparation de chlorhydrate de 9-hydroxy-3-(2-chloroéthyl)- 2-méthyl-4h-pyrido[1,2-a]pyrimidin-4-one
CN101245065B (zh) * 2007-02-14 2010-05-19 江苏恩华药业股份有限公司 制备苯并异噁唑衍生物的方法及其中间体
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
BRPI0815382A2 (pt) * 2007-07-31 2015-02-10 Otsuka Pharma Co Ltd Métodos para a produção de suspensão de aripiprazol e formulação de secagem por congelamento
ES2374200T3 (es) * 2007-08-21 2012-02-14 Teva Pharmaceutical Industries Ltd. Formulación de liberación prolongada de paliperidona.
WO2009056990A2 (fr) * 2007-08-21 2009-05-07 Actavis Group Ptc Ehf Polymorphes de la palipéridone
US7776866B2 (en) * 2007-09-15 2010-08-17 Protia, Llc Deuterium-enriched risperidone
US7977480B2 (en) 2007-12-10 2011-07-12 Synthon Bv Synthesis of paliperidone
DK2234617T3 (da) * 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
WO2009118655A2 (fr) * 2008-03-27 2009-10-01 Actavis Group Ptc Ehf Palipéridone de haute pureté ou sel pharmaceutiquement acceptable de celle-ci sensiblement exempte d’impureté céto
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
US8481729B2 (en) 2008-06-16 2013-07-09 Msn Laboratories Limited Processes for the preparation of paliperidone
CA2729056A1 (fr) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Forme cristalline de (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
CA2727573A1 (fr) * 2008-06-25 2009-12-30 Pfizer Inc. Composes diaryle et leurs utilisations
EP2138485A1 (fr) * 2008-06-26 2009-12-30 sanofi-aventis Dérivés substitués de N-oxyde pyrazine
EP2138488A1 (fr) * 2008-06-26 2009-12-30 sanofi-aventis Dérivés de 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-ones comme inhibiteurs de GSK3-beta utiles pour le traitement de maladies neurodégénératives
EP2138495A1 (fr) * 2008-06-26 2009-12-30 sanofi-aventis Dérivés substitués de pyrimido[2,1-a]isoquinolin-4-one
EP2138498A1 (fr) * 2008-06-26 2009-12-30 sanofi-aventis Dérivés tricycliques substitués contre les maladies neurodégénératives
EP2138492A1 (fr) * 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués de pyrimidin-4-one
EP2138494A1 (fr) * 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués d'alkyl pyrimidin-4-one
EP2138493A1 (fr) * 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués de pyrimidone
EP2318405A2 (fr) 2008-07-11 2011-05-11 Synthon B.V. Palipéridone cétone
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP2199293A1 (fr) 2008-12-22 2010-06-23 Chemo Ibérica, S.A. Procédé à étape unique pour la préparation de palipéridone en son sel d'oxalate
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
WO2010136895A1 (fr) 2009-05-28 2010-12-02 Actavis Group Ptc Ehf Formes à l'état solide de sels de palipéridone et leur procédé de préparation
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
SI2275423T1 (sl) 2009-07-13 2012-06-29 Krka D.D., Novo Mesto Postopek za sintezo paliperidona
EP2475663A2 (fr) 2009-09-10 2012-07-18 Actavis Group Ptc Ehf Palipéridone ou sel pharmaceutiquement acceptable de celui-ci sensiblement exempt d'impuretés
AU2010339689B2 (en) 2010-01-07 2015-02-19 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
WO2011114213A1 (fr) 2010-03-15 2011-09-22 Inventia Healthcare Private Limited Composition pharmaceutique stabilisée, à libération prolongée, comprenant un antipsychotique atypique
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US20130190299A1 (en) 2010-06-30 2013-07-25 Victoria Link Ltd. Methods and compositions for treatment of multiple sclerosis
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
WO2012035554A1 (fr) 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. Procédé amélioré de préparation de palipéridone très pure
CA2818025A1 (fr) 2010-11-15 2012-05-24 Agenebio, Inc. Derives de pyridazine, compositions et methodes de traitement d'une deficience cognitive
US9040695B2 (en) 2011-04-26 2015-05-26 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
WO2013095314A1 (fr) 2011-12-19 2013-06-27 Mahmut Bilgic Formulations pharmaceutiques comprenant de la rispéridone
WO2013100876A1 (fr) 2011-12-27 2013-07-04 Mahmut Bilgic Formulations de rispéridone
AU2013305938B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to paliperidone haptens and use thereof
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
CN104736565B (zh) * 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
ES2669565T3 (es) * 2012-08-21 2018-05-28 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
JP6538559B2 (ja) * 2012-09-28 2019-07-03 デルポー，インコーポレイティド 抗精神病薬の徐放のための装置及び方法
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
EP3083569B1 (fr) 2013-12-20 2022-01-26 Agenebio, Inc. Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
WO2016205739A1 (fr) 2015-06-19 2016-12-22 Belew Mekonnen Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
WO2024039886A1 (fr) 2022-08-19 2024-02-22 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128641A (en) * 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
US4443451A (en) * 1981-07-15 1984-04-17 Janssen Pharmaceutica N.V. Bicyclic pyrimidin-5-one derivatives
AU549582B2 (en) * 1981-07-30 1986-01-30 Dow Corning Corporation Silicone elastomer based roofing system
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US4529727A (en) * 1982-04-21 1985-07-16 Janssen Pharmaceutical, N.V. Pyrimido[2,1-b][1,3]-thiazines
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
US4458076A (en) * 1983-05-31 1984-07-03 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidinyl)-1,2-benzisothiazoles
EP0144101B1 (fr) * 1983-11-30 1991-02-06 Janssen Pharmaceutica N.V. N-(Hétérocycle bicyclyl)-4-pipéridinamines contenant des hétérocycles bicycliques
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4665075A (en) * 1984-12-05 1987-05-12 Janssen Pharmaceutica N.V. Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those

Also Published As

Publication number Publication date
IE58388B1 (en) 1993-09-08
DK168537B1 (da) 1994-04-18
HK108794A (en) 1994-10-14
SG119294G (en) 1995-03-17
DK143986A (da) 1986-09-28
AU5529786A (en) 1986-10-02
US4804663A (en) 1989-02-14
EP0196132A3 (en) 1988-01-20
AU579232B2 (en) 1988-11-17
JPH0613511B2 (ja) 1994-02-23
CA1256867A (fr) 1989-07-04
JPS61221186A (ja) 1986-10-01
EP0196132B1 (fr) 1992-08-12
CN86101906A (zh) 1986-10-01
SU1468419A3 (ru) 1989-03-23
BG60432B2 (bg) 1995-03-31
LU88576I2 (fr) 1995-03-21
CN1022566C (zh) 1993-10-27
NL940006I1 (nl) 1994-05-16
EP0196132A2 (fr) 1986-10-01
NL940006I2 (nl) 1999-09-01
IE860801L (en) 1986-09-27
DK143986D0 (da) 1986-03-26

Similar Documents

Publication Publication Date Title
SG119294G (en) 1,2-benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives
DE3662689D1 (en) Thiazolidinedione derivatives, their production and use
EP0207581A3 (en) Thiazolidine derivatives, their preparation and use
GB8621648D0 (en) Azole derivatives
GB2203146B (en) Thiazole derivatives
EP0202580A3 (en) 3,4-dihydrobenzopyran derivatives
ZA869591B (en) Substituted 5,6-dialkoxyquinazoline derivatives
GB2181730B (en) Isothiazolone derivatives
ZA868752B (en) 6,7,8,9-tetrahydro-10-methylpyrido(1,2-a)indol-9-amines and derivatives thereof
GB2174393B (en) Benzisothiazole derivatives
GB2176185B (en) N-(3 nitroquinolin-4-yl) guarnidine derivatives
GB2191197B (en) Benzothiazole derivatives
NZ214231A (en) 1,3,4-thiadiazole derivatives and pharmaceutical compositions
GB8507595D0 (en) Thiazole derivatives
LV5778B4 (lv) 1,2-Benzizoksazol-3-il- un 1,2-benzizotiazol-3-il-atvasinajumi
GB8531745D0 (en) 10beta-alkynyl-4-9(11)-estradiene derivatives
GB2179350B (en) 7-oxo-4-thia-1-azabicyclo3.2.0hept-2-ene derivatives
AU5067985A (en) 1,2,4-thiadiazole derivatives
GB8612161D0 (en) Azole derivatives
IE852872L (en) 1,3,4-thiadiazole derivatives
IE882071L (en) Certain 1,2-benzisoxazole and 1,2-benzisothiazole derivatives
ZA867715B (en) Isothiazolone derivatives
IE862662L (en) Isothiazolone derivatives
IE851072L (en) Thiazole derivatives
IE852236L (en) Benzisothiazole derivatives